Livongo Health, Inc. shares show a positive technical situation which suggests a continuation of the upward dynamic over the medium term. Investors have an opportunity to buy the stock and target the $ 176.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The tendency within the weekly time frame is positive above the technical support level at 57.21 USD
Low profitability weakens the company.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Based on current prices, the company has particularly high valuation levels.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Subsector Medical Equipment, Supplies & Distribution - NEC
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.